 |
Justin Petrone is the editor of GenomeWeb's BioArray News and covers the microarray and biochip sector of the genomics market. E-mail Justin Petrone or follow his GenomeWeb Twitter account at @BioArrayNews. |
CombiMatrix Bets on Array-Based Prenatal Testing, Affy Clinical Trials Deal to Drive Growth in H2
August 14, 2012
CombiMatrix Bets on Array-Based Prenatal Testing, Affy Clinical Trials Deal to Drive Growth in H2
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- CombiMatrix Sees Focus on CMA Pay off as it Reports 172 Percent Q4 Prenatal Testing Growth
January 8, 2013 / BioArray News - Study Finds Array-based Prenatal Testing More Informative than Standard Karyotyping
February 14, 2012 / BioArray News - Amid Market Exits and Acquisitions, 2012 Saw Arrays Gain Ground in Prenatal, DTC Markets
January 2, 2013 / BioArray News - NEJM Papers Support Use of Arrays in Prenatal Dx as Sequencing Gains Ground
December 11, 2012 / BioArray News - Autism-Associated Variants Uncovered by Population Diagnostics, SickKids Team Could Yield Dx Tests
December 11, 2012 / BioArray News